ClinicalTrials.gg
Not yet recruitingNCT06093828Updated Oct 23, 2023

Transcatheter Treatment of Tricuspid Valve Regurgitation

An interventional study of TriFlo Tricuspid Flow Optimizer in Symptomatic Severe Tricuspid Regurgitation, sponsored by TriFlo Cardiovascular, Inc.. Not yet recruiting at 4 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by TriFlo Cardiovascular, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tricuspid Valve Insufficiency with a site in Italy — 16 open to participants now, 19 under way, none of them phase 3. Tricuspid Valve Insufficiency · Italy.

Started
2024
with 2 others
No phase
8 of 32
2 open now
Primary completion
2027-01
later than 11 of 18 live
Registered
24th of 32
by date

Among the 32 studies in Tricuspid Valve Insufficiency with a site in Italy, this one is one of 3 that started in 2024, is one of 8 with no phase, reaches primary completion later than 11 of the 18 other live ones, and was the 24th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

16 of the 32 studies in Tricuspid Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tricuspid Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

Tricuspid Regurgitation induces an asymmetric enlargement of the tricuspid valve (TV) annulus causing a reduction of leaflets coaptation. Annular dilation continues even after surgical treatment. The progressive nature of TR, inadequate surgical treatment, and high-risk patient population make TR an ideal target for transcatheter therapy. The TriFlo TFO System introduces a new concept for the treatment of tricuspid regurgitation. Its commissural anchoring is designed to respect TV leaflet integrity, mobility, and maintain RV contractility.

Read the detailed description

This study is a prospective single-arm, multicenter pre-market study. Recent epidemiological data estimate the prevalence of significant tricuspid regurgitation (TR) in the general population to be as high as 0.55% (and up to 3% after 75 years of age), a prevalence comparable to aortic stenosis (AS) or mitral regurgitation (MR). Although the prevalence is high, TR is often not treated. In the United States, approximately 1.6 million patients live with moderate to severe TR, and fewer than 8,000 tricuspid surgeries are performed annually.

Clinically relevant TR is present in approximately 3.0 million individuals in Europe and 70 million people worldwide. Approximately 90% of TR in adults is functional (secondary) and can be due to left-sided myocardial or valvular disease, pulmonary vascular disease, right ventricular myopathy,chronic right ventricular volume overload, or idiopathic. Uncertainty about the impact of TR on outcomes is related to the heterogeneous nature of the tricuspid disease, which is often secondary to other conditions (mainly left-sided disease or pulmonary hypertension). In spite of its high prevalence, tricuspid valve disease is a largely untreated condition and is known to be associated with poor life expectancy.

The purpose of this clinical study is to evaluate the safety and clinical efficacy of the TriFlo Tricuspid Flow Optimizer in the treatment of severe TR.

03

Conditions studied

  • Symptomatic Severe Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age 18 years or older
  2. Symptomatic severe tricuspid regurgitation 3+ on a scale of 0+ to 5+, according to semi-quantitative echocardiographic color flow doppler evaluation
  3. Tricuspid valve (TV) morphology which fulfills anatomic criteria of eligibility for the device according to Imaging Core Lab assessment
  4. Signed (by subject or legal representative) and dated approved subject form prior to any study related procedure
  5. Available and able to return to the study site for post-procedural follow-up examination

Exclusion Criteria:

CARDIOVASCULAR EXCLUSION CRITERIA

  1. Requirement for an interventional percutaneous procedure or cardiac surgical procedure \<30 days before or after index procedure
  2. Prior tricuspid repair or replacement, implantation of an artificial heart valve.
  3. Active endocarditis or history of endocarditis within the previous 12 months.
  4. \<30%
  5. Severe aortic and mitral stenosis and/or regurgitation
  6. Severe tricuspid valve stenosis
  7. Severe right ventricular failure
  8. Systolic Pulmonary Artery pressure >70 mmHg
  9. Echocardiographic evidence of intracardiac mass, thrombus, tumor, myxoma or vegetation
  10. Femoral vein, inferior vena cava or evidence of intracardiac thrombus not adequately treated
  11. Presence of an occluded or thrombosed inferior vena cava (IVC) filter that would interfere with the delivery catheter, or ipsilateral deep vein thrombosis is present.
  12. Trans-tricuspid Pacemaker leads implanted within 90 days before the index procedure.

    EXCLUSION DUE TO COMORBIDITIES

  13. Cerebrovascular event within the previous 6 months.
  14. Myocardial infarction within 30 days prior to enrollment.
  15. Bleeding disorders or hypercoagulable state, thrombocytopenia ( count \<100,000/mm3), thrombocytosis (>750,000/mm3) or patient who refuses blood transfusions.
  16. Acute anemia \<8 g/dl not adequately treated or white blood cell count\<1000.
  17. Severe renal failure requiring chronic dialysis or \<25.
  18. Severe Liver disfunction - class C cirrhosis.
  19. Severe CLD with oxygen dependent .
  20. Coronary artery disease requiring revascularization

    EXCLUSION DUE TO

  21. Unable to undergo transesophageal echocardiogram (TEE) and cardiac computed tomography (CT) or screening TEE is unsuccessful.
  22. Contraindication, or known allergy to device's components (nickel or titanium), aspirin, anti-coagulation and antiplatelet therapy or contrast media that cannot be adequately pre-medicated.
  23. Known intolerance to anti-coagulation treatments.

    GENERAL EXCLUSION CRITERIA

  24. Female patient pregnant (urine HCG test result positive) or lactating.
  25. Known alcohol or drug abuser.
  26. Currently participating in the study of an drug or device.
  27. Neoplasia with \< 12 months
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Single-arm

    Single-arm: subjects with Tricuspid valve regurgitation who meet the study eligibility criteria

    Device: TriFlo Tricuspid Flow Optimizer

Interventions

  • DeviceTriFlo Tricuspid Flow Optimizer

    An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.

06

What researchers measure

Primary outcomes

  1. Acute safety, defined as freedom from device- or procedure-related Major Adverse Events (MAE)

    a composite of death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed TFO implantation, bleeding).

    Time frame: 30 days

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Jan 2027, 27 months later.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 27 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartEst.
Oct 2024
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2031
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06093828
Lead sponsor
TriFlo Cardiovascular, Inc.
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Oct 2024 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Dec 2031 (estimated)
Last update
Oct 23, 2023

Study contacts

Monica Tocchi, MD
Contact
m.tocchi@meditrial.eu
+39 06 45429780

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion